Immunity · 2023
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПоддержка правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Panpan, Song Ge, Liu Hejun, Yuan Meng, He Wan-Ting, Beutler Nathan, Zhu Xueyong, Tse Longping V, Martinez David R, Schäfer Alexandra, Anzanello Fabio, Yong Peter, Peng Linghang, Dueker Katharina, Musharrafieh Rami, Callaghan Sean, Capozzola Tazio, Limbo Oliver, Parren Mara, Garcia Elijah, Rawlings Stephen A, Smith Davey M, Nemazee David, Jardine Joseph G, Safonova Yana, Briney Bryan, Rogers Thomas F, Wilson Ian A, Baric Ralph S, Gralinski Lisa E, Burton Dennis R, Andrabi Raiees
Аннотация
Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against novel pandemic coronaviruses and to more effectively respond to SARS-CoV-2 variants. The emergence of Omicron and subvariants of SARS-CoV-2 illustrates the limitations of solely targeting the receptor-binding domain (RBD) of the spike (S) protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors, which targets a conserved S2 region in the betacoronavirus spike fusion machinery. Select bnAbs showed broad in vivo protection against all three deadly betacoronaviruses, SARS-CoV-1, SARS-CoV-2, and MERS-CoV, which have spilled over into humans in the past two decades. Structural studies of these bnAbs delineated the molecular basis for their broad reactivity and revealed common antibody features targetable by broad vaccination strategies. These bnAbs provide new insights and opportunities for antibody-based interventions and for developing pan-betacoronavirus vaccines.